Severe Infection clinical trials

Explore recruiting severe infection clinical trials.

Recruiting severe infection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial

France

Phase III and phase IV (Integrated) EU CTIS Study details

Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD

Denmark, Norway, Estonia

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-linked chronic granulomatous disease

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)

Germany, Czechia, Belgium, Spain, Italy, Bulgaria +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Severe Infection trials by city

Severe Infection in Toronto Severe Infection in Vancouver Severe Infection in Montreal Severe Infection in Calgary Severe Infection in Edmonton Severe Infection in Ottawa Severe Infection in Winnipeg Severe Infection in Quebec City Severe Infection in Hamilton Severe Infection in Kitchener Severe Infection in London Severe Infection in Halifax Severe Infection in New York Severe Infection in Los Angeles Severe Infection in Chicago Severe Infection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease